Towards antibacterial strategies: Studies on the mechanisms of interaction between antibacterial peptides and model membranes

Journal of Endotoxin Research

Volumn 9, Issue 2, 2003, Pages 67-84

  Wiese, Andre ^a   Gutsmann, Thomas ^a   Seydel, Ulrich ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CATHELICIDIN; COMPLEMENT; DEFENSIN; PHOSPHOLIPID; POLYMYXIN B; POLYPEPTIDE ANTIBIOTIC AGENT;

ANTIBACTERIAL ACTIVITY; BACTERIAL MEMBRANE; BACTERIAL SURVIVAL; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; INFLAMMATION; LIPID BILAYER; NONHUMAN; OUTER MEMBRANE; PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SEPSIS; SEPTIC SHOCK; STRAIN DIFFERENCE; SURFACE CHARGE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIAL OUTER MEMBRANE PROTEINS; HUMANS; LIPOPOLYSACCHARIDES; MEMBRANES, ARTIFICIAL; MODELS, BIOLOGICAL;

BACTERIA (MICROORGANISMS); ENTEROBACTERIACEAE; NEGIBACTERIA;

EID: 0037613601     PISSN: 09680519     EISSN: None     Source Type: Journal    
DOI: 10.1179/096805103125001441     Document Type: Review

References (169)

1. Kawasaki S, Moriguchi R, Sekiya K et al. The cell envelope structure of the lipopolysaccharide-lacking Gram-negative bacterium Sphingomonas paucimobilis. J Bacteriol 1994; 176: 284-290.
2. Nikaido H, Vaara M. Outer membrane. In: Neidhardt C, Ingraham JL, Brooks Low K, Magasanik B, Schaechter M, Umbarger HE. (eds) Escherichia coli and Salmonella typhimurium. Cellular and Molecular Biology. Washington, DC: American Society for Microbiology, 1987: 7-22.
3. Schumann RR, Leong SR, Flaggs GW et al. Structure and function of lipopolysaccharide binding protein. Science 1990; 249: 1429-1431.
4. Schromm AB, Brandenburg K, Rietschel ETh, Flad H-D, Carroll SF, Seydel U. Lipopolysaccharide binding protein (LBP) mediates CD14-independent intercalation of lipopolysaccharide into phospholipid membranes. FEBS Lett 1996; 399: 267-271.
5. Tapping RI, Gegner JA, Kravchenko VV, Tobias PS. Roles for LBP and soluble CD14 in cellular uptake of LPS. Prog Clin Biol Res 1998; 397: 73-78.
6. Tobias PS, Tapping RI, Gegner JA. Endotoxin interactions with lipopolysaccharide-responsive cells. Clin Infect Dis 1999; 28: 476-481.
7. Gutsmann T, Müller M, Carroll SF, MacKenzie RC, Wiese A, Seydel U. Dual role of lipopolysaccharide (LPS)-binding protein in neutralization of LPS and enhancement of LPS-induced activation of mononuclear cells. Infect Immun 2001; 69: 6942-6950.
8. Pfeiffer R. Untersuchungen über das Choleragift. Zf fur Hygiene 1892; 11: 393-412.
9. Lin J, Huang S, Zhang Q. Outer membrane proteins: key players for bacterial adaptation in host niches. Microbes Infect 2002; 4: 325-331.
10. Sen K, Hellman J, Nikaido H. Porin channels in intact cells of Escherichia coli are not affected by Donnan potentials across the outer membrane. J Biol Chem 1988; 263: 1182-1187.
11. Mueller P, Rudin DO, Tien HT. Reconstitution of cell membrane structure in vitro and its transformation into an excitable system. Nature 1962; 194: 979-981.
12. Tien HT. Bilayer Lipid Membranes (BLM): Theory and Practice. New York: Marcel Dekker, 1974.
13. Montal M, Mueller P. Formation of bimolecular membranes from lipid monolayers and a study of their electrical properties. Proc Natl Acad Sci USA 1972; 69: 3561-3566.
14. Schindler H, Feher G. Branched bimolecular lipid membranes. Biophys J 1976; 16: 1109-1113.
15. Schindler H. Formation of planar bilayers from artificial or native membrane vesicles. FEBS Lett 1980; 122: 77-79.
16. Osborn MJ, Gander JE, Parisi E, Carson J. Mechanism and assembly of the outer membrane of Salmonella typhimurium. J Biol Chem 1972; 247: 3962-3972.
17. White SH. The physical nature of planar bilayer membranes. In: Miller C. (ed) Ion Channel Reconstitution. New York: Plenum, 1986: 3-35.
18. Wiese A, Seydel U. Electrophysiological measurements on reconstituted outer membranes. Methods Mol Biol 2000; 145: 355-370.
19. Benz R, Janko K, Boos W, Läuger P. Formation of large, ion-permeable membrane channels by the matrix protein (porin) of Escherichia coli. Biochim Biophys Acta 1978; 511: 305-319.
20. Seydel U, Schröder G, Brandenburg K. Reconstitution of the lipid matrix of the outer membrane of Gram-negative bacteria as asymmetric planar bilayer. J Membr Biol 1989; 109: 95-103.
21. Babunashvili IN, Silberstein AY, Nenashev VA. Discrete changes of conductance and capacitance of bimolecular lipid membranes induced by liposomes. Studia Biophys 1981; 83: 131-137.
22. Benz R, Janko K. Voltage-induced capacitance relaxation of lipid bilayer membranes. Effects of membrane composition. Biochim Biophys Acta 1976; 455: 721-738.
23. Latorre R, Hall JE. Dipole potential measurements in asymmetric membranes. Nature 1976; 254: 361-363.
24. + complex as a probe for membrane asymmetry. Biophys J 1976; 15: 99-103.
25. Schoch P, Sargent DF, Schwyzer R. Capacitance and conductance as tools for the measurement of asymmetric surface potentials and energy barriers of lipid bilayer membranes. J Membr Biol 1979; 46: 71-89.
26. + complex. Z Naturforsch 1992; 47c: 757-761.
27. Wiese A, Reiners JO, Brandenburg K, Kawahara K, Zähringer U, Seydel U. Planar asymmetric lipid bilayers of glycosphingolipid or lipopolysaccharide on one side and phospholipids on the other: membrane potential, porin function, and complement activation. Biophys J 1996; 70: 321-329.
28. Struck DK, Hoekstra D, Pagano RE. Use of resonance energy transfer to monitor membrane fusion. Biochemistry 1981; 20: 4093-4099.
29. Schromm AB, Brandenburg K, Loppnow H et al. The charge of endotoxin molecules influences their conformation and IL-6-inducing capacity. J Immunol 1998; 161: 5464-5471.
30. Wu P, Brand L. Resonance energy transfer: methods and applications. Anal Biochem 1994; 218: 1-13.
31. Mantsch HH, McElhaney RN. Phospholipid phase transitions in model and biological membranes as studied by infrared spectroscopy. Chem Phys Lipids 1991; 57: 213-226.
32. Marcelja S. Chain ordering in liquid crystals. II. Structure of bilayer membranes. Biochim Biophys Acta 1974; 367: 165-176.
33. Blume A. A comparative study of the phase transition of phospholipid bilayers; and monolayers. Biochim Biophys Acta 1979; 557: 32-44.
34. Schwarz G, Taylor SE. Thermodynamic analysis of the surface activity exhibited by a largely hydrophobic peptide. Langmuir 1995; 11: 4341-4346.
35. Morgan BP. Physiology and pathophysiology of complement: progress and trends. Crit Rev Clin Lab Sci 1995; 32: 265-298.
36. Bhakdi S, Tranum-Jensen J. Membrane damage by complement. Biochim Biophys Acta 1983; 737: 343-372.
37. Müller-Eberhard HJ. The membrane attack complex. In: Müller-Eberhard HJ. (ed) Complement. New York: Springer, 1985: 227-278.
38. Bhakdi S, Tranum-Jensen J. Damage of mammalian cells by proteins that form transmembrane pores. Rev Physiol Biochem Pharmacol 1987; 107: 148-206.
39. Esser AF. The membrane attack complex of complement. Assembly, structure and cytotoxic activity. Toxicology 1994; 87: 229-247.
40. Tranum-Jensen J, Bhakdi S, Bhakdi-Lehnen B, Bjerrum OJ, Speth V. Complement lysis: the ultrastructure and orientation of the C5b-9 complex on target sheep erythrocyte membranes. Scand J Immunol 1978; 7: 45-56.
41. Tranum-Jensen J, Bhakdi S. Freeze-fracture: ultrastructural analysis of the complement lesion. J Cell Biol 1983; 97: 618-626.
42. Tschopp J. Ultrastructure of the membrane attack complex of complement heterogeneity of the complex caused by different degree of C9 polymerization. J Biol Chem 1984; 259: 7857-7863.
43. Zhang Y, Suankratay C, Zhang X-H, Lint TF, Gewurz H. Lysis via the lectin pathway of complement activation: minireview and lectin pathway enhancement of endotoxin-initiated hemolysis. Immunopharmacology 1999; 42: 81-90.
44. Jack DL, Jarvis GA, Booth CL, Turner MW, Klein NJ. Mannose-binding lectin accelerates complement activation and increases serum killing of Neisseria meningitidis serogroup C. J Infect Dis 2001; 184: 836-845.
45. Morrison DC, Kline LF. Activation of the classical and properdin pathways of complement by bacterial lipopolysaccharides (LPS). J Immunol 1977; 118: 362-368.
46. Vukajlovich SW, Hoffman J, Morrison DC. Activation of human serum complement by bacterial lipopolysaccharides: structural requirements for antibody independent activation of the classical and alternative pathway. Mol Immunol 1987; 24: 319-331.
47. Joiner KA, Hammer CH, Brown EJ, Cole RJ, Frank MM. Studies on the mechanism of bacterial resistance to complement-mediated killing I. Terminal complement components are deposited and released from Salmonella minnesota S218 without causing bacterial death. J Exp Med 1982; 155: 797-808.
48. Joiner KA, Hammer CH, Brown EJ, Frank MM. Studies on the mechanism of bacterial resistance to complement-mediated killing II. C8 and C9 release C5b67 from the surface of Salmonella minnesota S218 because the terminal complex does not insert into the bacterial outer membrane. J Exp Med 1982; 155: 809-819.
49. Merino S, Camprubí S, Albertí S, Benedí V-J, Tomás JM. Mechanisms of Klebsiella pneumoniae resistance to complement-mediated killing. Infect Immun 1992; 60: 2529-2535.
50. Ward CK, Inzana TJ. Resistance of Actinobacillus pleuropneumoniae to bactericidal antibody and complement is mediated by capsular polysaccharide and blocking antibody specific for lipopolysaccharide. J Immunol 1994; 153: 2110-2121.
51. del Castillo J, Rodriguez A, Romero CA, Sanchez V. Lipid films as transducers for detection of antigen-antibody and enzyme-substrate reactions. Science 1966; 153: 185-188.
52. Barfort P, Arquilla ER, Vogelhut P. Resistance changes in lipid bilayers: immunological applications. Science 1968; 160: 1119-1121.
53. Wobschall D, McKeon C. Step conductance increases in bilayer membranes induced by antibody-antigen-complement action. Biochim Biophys Acta 1975; 413: 317-321.
54. Michaels DW, Abramowitz AS, Hammer CH, Mayer MM. Increased ion permeability of planar lipid bilayer membranes after treatment with the C5b-9 cytolytic attack mechanism of complement. Proc Natl Acad Sci USA 1976; 73: 2852-2856.
55. Benz R, Schmid A, Wiedmer T, Sims PJ. Single-channel analysis of the conductance fluctuations induced in lipid bilayer membranes by complement proteins C5b-9. J Membr Biol 1986; 94: 37-45.
56. Young JDE, Cohn ZA, Podack ER. The ninth component of complement and the pore-forming protein (perforin 1) from cytotoxic T cells: structural, immunological, and functional similarities. Science 1986; 233: 184-190.
57. Young JDE, Young TM. Channel fluctuations induced by membrane attack complex C5b-9. Mol Immunol 1990; 27: 1001-1007.
58. Shiver JW, Dankert JR, Esser AF. Formation of ion-conducting channels by the membrane attack complex proteins of complement. Biophys J 1991; 60: 761-769.
59. Jackson MB, Stephens CL, Lecar H. Single channel currents induced by complement in antibody-coated cell membranes. Proc Natl Acad Sci USA 1981; 78: 6421-6425.
60. Mountz JD, Tien HT. Bilayer lipid membranes (BLM): study of antigen-antibody interactions. J Bioenerg Biomembr 1978; 10: 139-151.
61. Vukajlovich SW. Antibody-independent activation of the classical pathway of human serum complement by lipid A is restricted to Re-chemotype lipopolysaccharide and purified lipid A. Infect Immun 1986; 53: 480-485.
62. Vukajlovich SW, Sinoway P, Morrison DC. Activation of human serum complement by bacterial lipopolysaccharides. EOS J Immunol Immunopharmacol 1986; 6 (Suppl. 3): 73-75.
63. Mey A, Ponard D, Colomb M, Normier G, Binz H, Revillard J-P. Acylation of the lipid A region of Klebsiella pneumoniae LPS controls the alternative pathway activation of human complement. Mol Immunol 1994; 31: 1239-1246.
64. Clas F, Schmidt G, Loos M. The role of the classical pathway for the bactericidal effect of normal sera against Grain-negative bacteria. Curr Top Microbiol Immunol 1985; 121: 19-72.
65. Bjerre A, Brusletto B, Mollnes TE et al. Complement activation induced by purified Neisseria meningitidis lipopolysaccharide (LPS), outer membrane vesicles, whole bacteria, and an LPS-free mutant. J Infect Dis 2002; 185: 220-228.
66. Schröder G, Brandenburg K, Brade L, Seydel U. Pore formation by complement in the outer membrane of Gram-negative bacteria studied with asymmetric planar lipopolysaccharide/phospholipid bilayers. J Membr Biol 1990; 118: 161-170.
67. Wiese A, Grünewald P, Schaper K-J, Seydel U. Influence of acyl chain fluidity on the lipopolysaccharide-induced activation of complement. J Endotoxin Res 2001; 7: 147-154.
68. Münstermann M, Wiese A, Brandenburg K et al. Complement activation by bacterial surface glycolipids: a study with planar bilayer membranes. J Membr Biol 1999; 167: 223-232.
69. Hesketh TR, Payne SN, Humphrey JH. Complement and phospholipase C lysis of lipid membranes. Immunology 1972; 23: 705-711.
70. Devine DV, Wong K, Serrano K, Chonn A, Cullis PR. Liposome-complement interactions in rat serum: implications for liposome survival studies. Biochim Biophys Acta 1994; 1191: 43-51.
71. Oshima H, Soma G-I, Mizuno D. Gangliosides can activate human alternative complement pathway. Int Immunol 1993; 5: 1349-1351.
72. Elsbach P, Weiss J. Role of the bactericidal/permeability-increasing protein in host defence. Curr Opin Immunol 1998; 10: 45-49.
73. Elsbach P. The bactericidal/permeability-increasing protein (BPI) in antibacterial host defense. J Leukoc Biol 1998; 64: 14-18.
74. Levy O. A neutrophil-derived anti-infective molecule: bactericidal/permeability-increasing protein. Antimicrob Agents Chemother 2000; 44: 2925-2931.
75. Levy O, Elsbach P. Bactericidal/permeability-increasing protein in host defense and its efficacy in the treatment of bacterial sepsis. Curr Infect Dis Rep 2001; 3: 407-412.
76. Weiss J, Olsson I. Cellular and subcellular localization of the bactericidal/permeability-increasing protein of neutrophils. Blood 1987; 69: 652-659.
77. Canny G, Levy O, Furuta GT et al. Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci USA 2002; 99: 3902-3907.
78. Calafat J, Janssen H, Knol EF, Malm J, Egesten A. The bactericidal/permeability-increasing protein (BPI) is membrane-associated in azurophil granules of human neutrophils, and relocation occurs upon cellular activation. APMIS 2000; 108: 201-208.
79. Weiss J, Elsbach P, Olsson I, Odeberg H. Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes. J Biol Chem 1978; 253: 2664-2672.
80. 2 from rabbit polymorphonuclear leukocytes. J Biol Chem 1979; 254: 11000-11009.
81. Gazzano-Santoro H, Parent JB, Grinna L et al. High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide. Infect Immun 1992; 60: 4754-4761.
82. 23. Infect Immun 1995; 63: 2201-2205.
83. 2-terminal fragment carries all the antibacterial activities of the human neutrophil 60-kDa bactericidal/permeability-increasing protein. J Biol Chem 1987; 262: 14891-14894.
84. Ooi CE, Weiss J, Doerfler ME, Elsbach P. Endotoxin-neutralizing properties of the 25 kD N-terminal fragment of the 55-60 kD bactericidal/permeability-increasing protein of human neutrophils. J Exp Med 1991; 174: 649-655.
85. 2-terminal-fragment with isolated LPS and intact Proteus mirabilis and Escherichia coli. Infect Immun 1994; 62: 259-265.
86. Huang K, Fishwild DM, Wu H-M, Dedrick RL. Lipopolysaccharide-induced E-selectin expression requires continuous presence of LPS and is inhibited by bactericidal/permeability-increasing protein. Inflammation 1995; 19: 389-404.
87. Weiss J, Franson RC, Beckerdite S, Schmeidler K, Elsbach P. Partial characterization and purification of a rabbit granulocyte factor that increases permeability of Escherichia coli. J Clin Invest 1975; 55: 33-42.
88. Weiss J, Muello K, Victor M, Elsbach P. The role of lipopolysaccharides in the action of the bactericidal/permeability-increasing neutrophil protein on the bacterial envelope. J Immunol 1984; 132: 3109-3115.
89. Elsbach P, Weiss J. The bactericidal/permeability-increasing protein (BPI), a potent element in host-defense against Gram-negative bacteria and lipopolysaccharide. Immunobiology 1993; 187: 417-429.
90. 23) on cerebrospinal fluid inflammation induced by endotoxin. J Infect Dis 1995; 171: 948-953.
91. 23 attenuates endotoxin-induced cardiovascular depression in awake rabbits. Shock 1995; 4: 74-78.
92. 23) decreases Escherichia coli-induced mortality and organ injury during immunosuppression-related neutropenia. Shock 1995; 4: 298-306.
93. 23) on neutrophil activity in burned rats. J Trauma 1996; 40: 886-892.
94. 21) in baboon sepsis is related to its antibacterial, not antiendotoxin, properties. Ann Surg 1999; 229: 262-271.
95. Wiese A, Brandenburg K, Lindner B et al. Mechanisms of action of the bactericidal/permeability-increasing protein BPI on endotoxin and phospholipid monolayers and aggregates. Biochemistry 1997; 36: 10301-10310.
96. Beamer LJ, Carroll SF, Eisenberg D. Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. Science 1997; 276: 1861-1864.
97. Wiese A, Brandenburg K, Carroll SF, Rietschel ETh, Seydel U. Mechanisms of action of bactericidal/permeability-increasing protein BPI on reconstituted outer membranes of Gram-negative bacteria. Biochemistry 1997; 36: 10311-10319.
98. Zanetti M, Gennaro R, Romeo D. Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett 1995; 374: 1-5.
99. Cowland JB, Johnsen AH, Borregaard N. hCAP-18, a cathelin/pro-bactenecin-like protein of human neutrophil specific granules. FEBS Lett 1995; 368: 173-176.
100. Malm J, Sørensen O, Persson T et al. The human cationic antimicrobial protein (hCAP-18) is expressed in the epithelium of human epididymis, is present in seminal plasma at high concentrations, and is attached to spermatozoa. Infect Immun 2000; 68: 4297-4302.
101. Sørensen O, Cowland JB, Askaa J, Borregaard N. An ELISA for hCAP-18, the cathelicidin present in human neutrophils and plasma. J Immunol Methods 1997; 206: 53-59.
102. Frohm M, Gunne H, Bergman AC et al. Biochemical and antibacterial analysis of human wound and blister fluid. Eur J Biochem 1996; 237: 86-92.
103. Agerberth B, Grunewald J, Castanos-Velez E et al. Antibacterial components in bronchoalveolar lavage fluid from healthy individuals and sarcoidosis patients. Am J Respir Crit Care Med 1999; 160: 283-290.
104. Bals R, Wang X, Zasloff M, Arilson JM. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci USA 1998; 95: 9541-9546.
105. Agerberth B, Charo J, Werr J et al. The human antimicrobial and chemotactic peptides LL-37 and α-defensins are expressed by specific lymphocyte and monocyte populations. Blood 2000; 96: 3086-3093.
106. Conner K, Nern K, Rudisill J, O'Grady T, Gallo RL. The antimicrobial peptide LL-37 is expressed by keratinocytes in Condyloma acuminatum and Verruca vulgaris. J Am Acad Dermatol 2002; 47: 347-350.
107. Hirata M, Zhong J, Wright SC, Larrick JW. Structure and functions of endotoxin-binding peptides derived from CAP18. Prog Clin Biol Res 1995; 392: 317-326.
108. de Haas CJ, Haas PJ, van Kessel KP, van Strijp JA. Affinities of different proteins and peptides for lipopolysaccharide as determined by biosensor technology. Biochem Biophys Res Commun 1998; 252: 492-496.
109. Travis SM, Anderson NN, Forsyth WR et al. Bactericidal activity of mammalian cathelicidin-derived peptides. Infect Immun 2000; 68: 2748-2755.
110. Larrick JW, Hirata M, Shimomoura Y et al. Antimicrobial activity of rabbit CAP18-derived peptides. Antimicrob Agents Chemother 1993; 37: 2534-2539.
111. Basañez G, Shinnar AE, Zimmerberg J. Interaction of hagfish cathelicidin antimicrobial peptides with model lipid membranes. FEBS Lett 2002; 532: 115-120.
112. Benz R. Uptake of solutes through bacterial outer membranes. In: Ghuysen J-M, Hakenbeck R. (eds) Bacterial Cell Wall. Amsterdam: Elsevier, 1984: 397-423.
113. Gutsmann T, Larrick JW, Seydel U, Wiese A. Molecular mechanisms of interaction of rabbit CAP18 with outer membranes of Gram-negative bacteria. Biochemistry 1999; 38: 13643-13653.
114. Kaca W, Radziejewska-Lebrecht J, Bhat UR. Effect of polymyxins on the lipopolysaccharide-defective mutants of Proteus mirabilis. Microbios 1990; 61: 23-32.
115. Guina T, Yi EC, Wang H, Hackett M, Miller SI. A PhoP-regulated outer membrane protease of Salmonella enterica serovar typhimurium promotes resistance to alpha-helical antimicrobial peptides. J Bacteriol 2000; 182: 4077-4086.
116. Bakker EP, Mangerich WE. Interconversion of components of the bacterial proton motive force by electrogenic potassium transport. J Bacteriol 1981; 147: 820-826.
117. Ganz T, Lehrer RI. Defensins. Pharmacol Ther 1995; 66: 191-205.
118. Lehrer RI, Ganz T. Defensins of vertebrate animals. Curr Opin Immunol 2002; 14: 96-102.
119. Schröder JM, Harder J. Human beta-defensin-2. Int J Biochem Cell Biol 1999; 31: 645-651.
120. Harder J, Bartels J, Christophers E, Schröder JM. Isolation and characterization of human β-defensin-3, a novel human inducible peptide antibiotic. J Biol Chem 2001; 276: 5707-5713.
121. Martin E, Ganz T, Lehrer RI. Defensins and other endogenous peptide antibiotics of vertebrates. J Leukoc Biol 1995; 58: 128-135.
122. Schröder JM. Epithelial peptide antibiotics. Biochem Pharmacol 1999; 57: 121-134.
123. Ganz T. Epithelia: not just physical barriers. Proc Natl Acad Sci USA 2002; 99: 3357-3358.
124. Osborn RW, De Samblanx GW, Thevissen K et al. Isolation and characterisation of plant defensins from seeds of Asteraceae, Fabaceae, Hippocastanaceae and Saxifragaceae. FEBS Lett 1995; 368: 257-262.
125. White SH, Wimley WC, Selsted ME. Structure, function, and membrane integration of defensins. Curr Opin Struct Biol 1995; 5: 521-527.
126. Sawyer JG, Martin NL, Hancock REW. Interaction of macrophage cationic proteins with the outer membrane of Pseudomonas aeruginosa. Infect Inumm 1988; 56: 693-698.
127. Lehrer RI, Barton A, Daher KA, Harwig SSL, Ganz T, Selsted ME. Interaction of human defensins with Escherichia coli. J Clin Invest 1989; 84: 553-561.
128. Hill CP, Yee J, Selsted ME, Eisenberg D. Crystal structure of defensin HNP-3, an amphiphilic dimer: mechanisms of membrane permeabilization. Science 1991; 251: 1481-1485.
129. Selsted ME, Ouellette AJ. Defensins in granules of phagocytic and non-phagocytic cells. Trends Cell Biol 1995; 5: 114-119.
130. Kagan BL, Selsted ME, Ganz T, Lehrer RI. Antimicrobial defensin peptides form voltage-dependent ion-permeable channels in planar lipid bilayer membranes. Proc Natl Acad Sci USA 1990; 87: 210-214.
131. Hristova K, Selsted ME, White SH. Critical role of lipid composition in membrane permeabilization by rabbit neutrophil defensins. J Biol Chem 1997; 272: 24224-24233.
132. Storm DR, Rosenthal K. Polymyxin and related peptide antibiotics. Annu Rev Biochem 1977; 46: 723-763.
133. El Mashak EM, Tocanne JF. Polymyxin B-phosphatidylglycerol interactions. A monolayer (π, ΔV) study. Biochim Biophys Acta 1980; 596: 165-179.
134. Vaara M, Vaara T. Polycations as outer membrane disorganizing agents. Antimicrob Agents Chemother 1983; 24: 114-122.
135. Hancock REW. Alterations in outer membrane permeability. Annu Rev Microbiol 1984; 38: 237-264.
136. Vaara M. Agents that increase the permeability of the outer membrane. Microbiol Rev 1992; 56: 395-411.
137. Schindler PRG, Teuber M. Ultrastructural study of Salmonella typhimurium treated with membrane active agents: specific reaction of dansylchloride with cell envelope components. J Bacteriol 1978; 135: 198-206.
138. Schindler PRG, Teuber M. Action of polymyxin B on bacterial membranes: morphological changes in the cytoplasm and in the outer membrane of Salmonella typhimurium and Escherichia coli B. Antimicrob Agents Chemother 1975; 8: 95-104.
139. Theretz A, Theissie J, Tocanne JF. A study of the structure and dynamics of complexes between polymyxin B and phosphatidylglycerol in monolayers by fluorescence. Eur J Biochem 1984; 142: 113-119.
140. 1 nonapeptide with phosphatidic acid monolayer and bilayer membranes. Chem Phys Lipids 1988; 47: 155-163.
141. Imai M, Inoue K, Nojima S. Effect of polymyxin B on liposomal membranes derived from Escherichia coli lipids. Biochim Biophys Acta 1975; 375: 130-137.
142. Ranck JL, Tocanne JF. Polymyxin B induces interdigitation in dipalmitoylphosphatidylglycerol lamellar phase with stiff hydrocarbon chains. FEBS Lett 1982; 143: 175-178.
143. Mushayakarara E, Levin IW. Effects of polypeptide-phospholipid interactions on bilayer reorganizations. Raman spectroscopic study of the binding of polymyxin B to dimyristoylphosphatidic acid and dimyristoylphosphatidylcholine dispersions. Biochim Biophys Acta 1984; 769: 585-595.
144. Sixl F, Watts A. Deuterium and phosphorous nuclear magnetic resonance studies on the binding of polymyxin B to lipid bilayer-water interfaces. Biochemistry 1985; 24: 7906-7910.
145. Feingold DS, HsuChen CC, Sud IJ. Basis for the selectivity of action of the polymyxin antibiotics on cell membranes. Ann NY Acad Sci 1974; 235: 480-492.
146. Antonov VF, Korepanova EA, Vladimirov YA. Bilayer membranes charged by detergents as model to study the role of the surface charge in ionic permeability. Studia Biophys 1976; 58: 87-101.
147. Miller IR, Bach D, Teuber M. Effect of polymyxin B on the structure and the stability of lipid layers. J Membr Biol 1978; 39: 49-56.
148. Zhang L, Dhillon P, Yan H, Farmer S, Hancock REW. Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000; 44: 3317-3321.
149. Daugelavicius R, Bakiene E, Bamford DH. Stages of polymyxin B interaction with the Escherichia coli cell envelope. Antimicrob Agents Chemother 2000; 44: 2969-2978.
150. Srimal S, Surolia N, Balasubramanian S, Surolia A. Titration calorimetric studies to elucidate the specificity of the interactions of polymyxin B with lipopolysaccharides and lipid A. Biochem J 1996; 315: 679-686.
151. Thomas CJ, Gangadhar BP, Surolia N, Surolia A. Kinetics and mechanism of the recognition of endotoxin by polymyxin B. J Am Chem Soc 1998; 120: 12428-12434.
152. Thomas CJ, Surolia A. Kinetics of the interaction of endotoxin with polymyxin B and its analogs: a surface plasmon resonance analysis. FEBS Lett 1999; 445: 420-424.
153. Thomas CJ, Surolia N, Surolia A. Surface plasmon resonance studies resolve the enigmatic endotoxin neutralizing activity of polymyxin B. J Biol Chem 1999; 274: 29624-29627.
154. Kubesch P, Boggs J, Luciano L, Maass G, Tümmler B. Interaction of polymyxin B nonapeptide with anionic phospholipids. Biochemistry 1987; 26: 2139-2149.
155. Boggs JM, Rangaraj G. Phase transitions and fatty acid spin label behavior in interdigitated lipid phases induced by glycerol and polymyxin. Biochim Biophys Acta 1985; 816: 221-233.
156. Peterson A, Hancock REW, McGroarty EJ. Binding of polycationic antibiotics and polyamines to lipopolysaccharides of Pseudomonas aeruginosa. J Bacteriol 1985; 164: 1256-1261.
157. Schröder G, Brandenburg K, Seydel U. Polymyxin B induces transient permeability fluctuations in asymmetric planar lipopolysaccharide/phospholipid bilayers. Biochemistry 1992; 31: 631-638.
158. Wiese A, Münstermann M, Gutsmann T et al. Molecular mechanisms of polymyxin B-membrane interactions: direct correlation between surface charge density and self-promoted transport. J Membr Biol 1998; 162: 127-138.
159. Vaara M, Vaara T, Jensen M et al. Characterization of the lipopolysaccharide from the polymyxin-resistant pmrA mutants of Salmonella typhimurium. FEBS Lett 1981; 129: 145-149.
160. Nummila K, Kilpeläinen I, Zähringer U, Vaara M, Helander IM. Lipopolysaccharides of polymyxin B-resistant mutants of Escherichia coli are extensively substituted by 2-aminoethyl pyrophosphate and contain aminoarabinose in lipid A. Mol Microbiol 1995; 16: 271-278.
161. Helander IM, Kato Y, Kilpeläinen I et al. Characterization of lipopolysaccharides of polymyxin-resistant and polymyxin-sensitive Klebsiella pneumoniae O3. Eur J Biochem 1996; 237: 272-278.
162. Seltmann G, Lindner B, Holst O. Resistance of Serratia marcescens to polymyxin B: a comparative investigation of two S-form lipopolysaccharides obtained from a sensitive and a resistant variant of strain 111. J Endotoxin Res 1996; 3: 497-504.
163. Rahaman SO, Mukherjee J, Chakrabarti A, Pal S. Decreased membrane permeability in a polymyxin B-resistant Escherichia coli mutant exhibiting multiple resistance to beta-lactams as well as aminoglycosides. FEMS Microbiol Lett 1998; 161: 249-254.
164. Yethon JA, Gunn JS, Ernst RK et al. Salmonella enterica serovar Typhimurium waaP mutants show increased susceptibility to polymyxin and loss of virulence in vivo. Infect Immun 2000; 68: 4485-4491.
165. Ernst RK, Guina T, Miller SI. How intracellular bacteria survive: surface modifications that promote resistance to host innate immune responses. J Infect Dis 1999; 179 (Suppl 2): S326-S330.
166. Ernst RK, Guina T, Miller SI. Salmonella typhimurium outer membrane remodeling: role in resistance to host innate immunity. Microbes Infect 2001; 3: 1327-1334.
167. Liechty A, Chen J, Jain MK. Origin of antibacterial stasis by polymyxin B in Escherichia coli. Biochim Biophys Acta 2000; 1463: 55-64.
168. Brodsky IE, Ernst RK, Miller SI, Falkow S. mig-14 is a Salmonella gene that plays a role in bacterial resistance to antimicrobial peptides. J Bacteriol 2002; 184: 3203-3213.
169. Gutsmann T, Hagge SO, Larrick JW, Seydel U, Wiese A. Interaction of CAP18-derived peptides with membranes made from endotoxins or phospholipids. Biophys J 2001; 80: 2935-2945.